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1. Introduction 
There is growing body of evidence that many diseases require a systemic treatment 
approach rather than targeting just a single enzyme or receptor. Neurodegenerative diseases 
affect a wide spectrum of the population and, in most cases, lead to physical and/or mental 
incapacity, involving memory, cognition, language and personality. Aging contributes to 
the development of neurodegeneration by shifting the equilibrium between oxygen-
dependent and independent mechanisms of energy production towards mitochondria-
generated ATP. Mitochondrial capacity degenerates with aging, making cells susceptible to 
both ischemic and oxidative insults. Although all mechanisms of hypoxic preconditioning 
are very far from complete understanding, it is clear that cell is equipped with the necessary 
molecular machinery to respond to the changes in intracellular oxygen content.  However, 
aging significantly compromises this response. Turning on the existent molecular machinery 
to compensate for hypoxic and oxidative stress may lead to comprehensive and safe 
therapeutic strategy for age-related neurodegenerative disorders. 
To restore homeostatic balance destroyed as a result of acute or chronic injury, one needs to 
activate intrinsic genetic programs silent or insufficiently active in the damaged cells. 
Activation of cellular defensive systems requires stabilization of corresponding transcription 
factors which govern expression of cassettes of genes turning on a particular program such as 
antioxidant, anti-inflammatory, or anti-hypoxic one. Hence, one of the emerging strategies in 
drug screening becomes a hunt for activators (or inhibitors) of transcription factors. In some 
cases there is an enzyme responsible for a rate-limiting conversion of a transcription factor, in 
some not.  The well-known and commonly used approach to screening of activators of 
transcription factors is the use of luciferase gene cloned under the promoter activated by a 
specified transcription factor. For example, cell-based screening for activators of hypoxia 
induced factor 1 (HIF1) is performed using HRE (hypoxia response element)-luciferase 
(Semenza et al 1996), and for Nrf2 – using ARE (antioxidant response element)-luciferase 
reporter assay (Moehlenkamp & Johnson 1999). Promega has just begun to offer commercially 
such type of constructs with any desired promoter for research and drug screening purposes.  
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Although these reporters are obviously of great help in research, they provide an integrated 
response and are affected by many steps such as transcription factor stabilization, 
phosphorylation, translocation to nucleus, interaction with transcription cofactors, etc. As a 
result, the response of these reporters is not immediate: it is delayed by many hours, the 
magnitude of activation effect is very modest, and there is always uncertainty in the actual site 
of their effect along the path leading to activation of a particular promoter.  
The important general pathway effectively regulating the cellular response to hypoxia, 
oxidation and inflammation is specific regulation of protein stability of the corresponding 
transcription factors or their modulators by ubiquitination and proteasomal degradation. 
Protein degradation by the proteasome is one of the major regulatory mechanisms in the 
cell. The proteasome mediates the degradation of most short-lived proteins that control cell 
cycle, transcription, DNA repair, apoptosis and other cellular processes. Under normal 
conditions, the stress response transcription factors are expressed constitutively, but on the 
protein level, these transcriptional factors are unstable: they undergo ubiquitination either 
directly, or upon specific covalent modification(s) of the targeted amino acids residues (like 
hypoxia inducible factor, HIF). Considering the protein stability of transcription factors as 
the most important and limiting step in the stress response we have recently developed a 
different approach to high throughput screening (HTS) of stabilizers of transcription factors. 
The approach is based on stable expression of a fusion between luciferase and a 
transcription factor minimum domain recognized by ubiquitination machinery (Fig.1). 
Minimum domain is the portion of a transciption factor that is necessary and sufficient for 
recognition and ubiquitination steps to occur. The overexpressed luciferase-labeled 
surrogate of a transcription factor undergoes the same recognition and transformation steps 
as an endogenous one. The time-course of reporter signal changes can be easily followed: 
the luminescent readings are extremely sensitive and provide monitoring just minutes after 
drug administration.  
This new approach to HTS was developed in this laboratory and successfully used to 
discover novel activators of HIF1 and Nrf2 as exemplified below.  
2. Development, validation and application of novel reporters for the 
purposes of HTS 
2.1 Neh2-luciferase reporter construction and performance (Smirnova et al 2011) 
The key transcription factor that orchestrates antioxidant response is Nrf2 (Moi et al 1994, 
Motoyashi & Yamamoto 2004, Kaspar et al 2009). Compounds that activate Nrf2 make the 
cell more resistant to subsequent xenobiotic attack or oxidative stress. This has major 
implications for human health: (1) Nrf2 activators can be considered as medications for 
cancer prevention; (2) while an increased level of Nrf2 makes cancerous cells more resistant 
to chemotherapy; and (3) Nrf2 activators can both prevent and treat neurodegenerative 
diseases. There is a consensus that oxidative stress either derived from gene mutations or 
environmental toxins is a mediator of neurodegenerative diseases and thus, Nrf2 has been 
justified as a pharmacological target for neuroprotective therapies in Parkinson’s, 
Huntington’s and other neurodegenerative diseases. 
2.1.1 Nrf2 - Keap1 interaction mode 
Nrf2 is composed of Neh1–Neh6 domains, among which Neh2 (1-98 aa) is the putative 
negative regulatory domain that interacts with Keap1, while Neh4 and Neh5 are 
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transactivation domains, and Neh1 is the binding domain for ARE. The functional domains 
of Keap1 are the Broad complex, Tramtrack and Bric-a-Brac, the intervening region, the 
double glycine repeats domain, and the C-terminal region (Zhang et al 2006). Two motifs in 
the Neh2 domain, i.e. ETGE and DLG (Tong et al 2006 a, 2006b), are recognized by the 
Keap1 homodimer in a hinge-latch mode (see Fig.2 and 3). Keap1 mediates 
polyubiquitination of the lysines positioned within the central α-helix of the Neh2 domain 
under homeostatic conditions. Under oxidative/electrophilic stress, most reactive cysteines 
within Keap1 (Cys 151, Cys273, Cys288) are modified and Keap1 undergoes conformational 
changes which lead to Nrf2 stabilization (see Fig.3) (Cullinan et al 2004). 
 
 
 
Fig. 1. Schematic presentation of reporter performance based on constitutive expression of 
luciferase-labeled minimum domain of a transcription factor. The background luminescent 
signal corresponds to the sum of all forms of labeled surrogate except for its proteolytic 
fragments: [MD-luc]= Ko(1/ki). Specific stabilizers of a transcription factor must work at 
the recognition step: each reporter requires validation to demonstrate that this particular 
step is rate-limiting, meaning that  [MD-luc]= Ko(1/k1). If this is the case, HTS will select 
for specific stabilizers of a transcription factor working at the recognition step. 
 
 
Fig. 2. Schematic presentation of domain structures of Keap 1 and Nrf2. 
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Nrf2 translocates to the nucleus, interact with Maf protein, and induces expression of the 
cytoprotective enzymes such as glutathione reductase, thioredoxin reductase, glutathione S-
transferase (GST), hemeoxygenase-1 (HO1), catalase, etc. Alkylating agents are supposed to 
target Cys151 to detach Cul3 ubiquitin-ligase and inhibit ubiquitination (Zhang et al 2004). 
Keap1 thiols Cys273 and Cys 288 are supposedly responsible for dimer conformation 
capable of binding Nrf2: changes in Keap1 conformation disrupt dimeric structure and also 
result in inhibition of ubiquitination. The yet unknown specific stabilizers of Nrf2 should 
disrupt interaction between DLG domain of Nrf2 and Keap1 and thus prevent 
ubiquitination of Neh2 lysines and result in Nrf2 stabilization. 
 
 
Fig. 3. Schematic presentation of Nrf2 stabilization and transcription activation (left) versus 
the performance of Neh2-luc reporter (right). Keap1-bound Nrf2 is subject to ubiquitination, 
and then underegoes proteasomal degradation. Upon oxidative stress, Keap1 thiols are 
either alkylated (Cys 151) resulting in detachment of Cul3 ubiquitin ligase or modified 
(Cys273 and Cys288) leading to a conformation change in Keap1 dimer and release of Nrf2 
from the complex. In both cases Nrf2 protein is stabilized, and the same mechanism of 
stabilization applies to the Neh2-luc reporter performance. Luciferase labeling of Neh2 
permits easy monitoring of fusion accumulation upon oxidative stress induced by small 
molecule activators.  
2.1.2 Neh2-luciferase reporter validation 
The Pcmv-driven Neh2-luc reporter supports the constitutive, intracellular synthesis of a 
novel fusion protein composed of the Neh2 domain and firefly luciferase in human 
neuroblastoma cell line SH-SY5Y.  Validation studies (see Smirnova et al 2011) included: (1) 
Testing of canonical activators of Nrf2, such as 15-deoxy-prostaglandin J2 (15d-PGJ2), 
sulforaphane and tert-butylhydroquinone (TBHQ), which were shown to produce a 
significant increase (> 20-fold) in the background luciferase signal within 3-4 h following the 
treatment of SH-SY5Y human neuroblastoma cells stably expressing the Neh2 reporter; (2) 
Forced expression of Keap1 in the Neh2- luc reporter cell line led to a 3.5-fold decrease in 
the background luminescence; (3) Keap1 reduction by siRNA resulted in a steady state 
increase in Neh2-luc reporter luminescence and an induction of transcription of Nrf2-
regulated genes; (4) Immunoblot with antibodies against luciferase confirmed that an 
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increase in luminescence corresponds to the accumulation of the fusion protein upon 
incubation with commonly used Nrf2 activators. Validation studies demonstrated that 
Keap1 regulates the stability of the Neh2-reporter in the same manner as for endogenous 
Nrf2 and that the rate-limiting step in Neh2-luc cell line is controlled by the disruption of 
the Neh2-Keap1 complex which results in inhibition of ubiquitinylation. The Neh2-luc 
reporter system is a novel tool to monitor the direct effect of a particular compound on the 
first step controlling Nrf2 stability, i.e. Nrf2-Keap1 and/or Keap1-Cul3 interaction. 
2.1.3 Neh2-luciferase reporter sensitivity 
All manual screenings were performed using 96-well plates with 100 L serum per well 
dispensed with WellMate multichannel dispenser from Matrix (Thermo Fisher Scientific). 
Drugs were added after overnight culture incubation, 3hr later serum removed, lysis buffer 
added, and luminescence measured with either BrightGlo reagent (Promega) or common 
luciferase reagent made by ourselves. The background luminescence signal calibrated with 
recombinant luciferase allows us to estimate the steady-state concentration of the Neh2-
luciferase fusion protein: the backround is ca. 15-20 rlu, which corresponds to 0.25-0.33 pg 
luciferase protein and is more than two orders of magnitude lower than that observed for 
the cell line expressing wild-type luciferase under control of the same promoter. The low 
steady state luciferase activity (recalculated as 0.6-0.8 nM fusion protein for 30,000 cell/well 
density and 233 3 single cell volume) suggests that in spite of the forced expression of the 
Neh2-luciferase fusion protein, it is successfully recognized by the endogenous Keap1-Cul3 
complex and almost fully degraded. The reporter exemplifies the action of an “ideal Nrf2 
activator” which stabilizes endogenous Nrf2 by competing for Keap1 binding and not by 
modifying Keap1 chemically. The new reporter is advantageous over the ARE-luc reporter 
or especially ARE-GFP reporter (Shaw et al 2010) and other methods such as 
immunoblotting of Nrf2 (or luciferase in our case) or RT-PCR of Nrf2-induced genes 
because all other methods are at least 5-6 hr delayed as compared to immediate response of 
the newly constructed reporter. Moreover, ARE-luc reporter background signal is at the 
single rlu digits and activation for TBHQ is only 3-fold compare to 16-20 fold activation in 
the case of Neh2-luc reporter (see Smirnova et al 2011).  
There are no examples of the literature on the application of the same approach to screening 
purposes, except for the recently publsihed paper on the reporter construct expressing a 
fusion between three domains of Nrf2 and beta-galactosidase (Hirotsu et al 2011). The 
authors validated the construct and showed the advantages of the reporter over the 
commonly used ARE-luciferase. Nrf2d-LacZ protein consists of Nrf2 N-terminal region 
(containing Neh2, Neh4, and Neh5) and SV40 nuclear localization signals (NLS)–-
galactosidase, it is specific to Nrf2 activators. However, the Nrf2d-LacZ reporter it is still 
less sensitive than the one developed in our laboratory. Nrf2d-LacZ reporter provides ca. 5-
fold activation over the background signal upon addition of a classic Nrf2 activator, TBHQ, 
and requires at least 1 hr incubation to get the first time-point (see Fig 3C in Hirotsu et al 
2011), compared to 20-fold activation for TBHQ (see above) and the possibility to minotor 
the reporter effect minutes after drug addition. 
2.1.4 Neh2-luciferase reporter optimization for HTS format 
For HTS purposes, the assay was optimized to 384-well format: SH-SY5Y-Neh2-luc cells 
were plated into 384 well, white, flat-bottom plates at 7000 cell/well in 30 l serum and 
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incubated overnight at 37oC, 5% CO2. The next day compounds were added to two final 
concentrations of 10 M and 20 M, plates were incubated for 3 hr at 370C, and luciferase 
activity was measured using SteadyGloTM reagent (Promega). Each plate had two internal 
standards, TBHQ (100%) and DMSO (0%). This format provides Z values above 0.7. The 
reporter activation (%) was calculated as a ratio (L–LDMSO)/(LTBHQ-LDMSO). Hits were defined 
as those greater than 25%. The pilot screen of Spectrum library revealed 224 hits exhibiting 
Neh2-luc reporter activity equal or higher than  25% of TBHQ; among those, 100 showed 
activation of at least 75% of that induced by TBHQ. Thus, 5% of biologically active 
compounds and drugs presented in the Spectrum library are at least 75% as potent as TBHQ 
in activation of Nrf2. The prevalence of hits does not indicate the low specificity of the 
reporter, it simply reflects the important role that Nrf2 plays in xenobiotic detoxification of a 
large number of chemical entities. Ideally, any compound disturbing cellular redox balance 
should be a hit in Neh2-luc screen. 
HTS of Spectrum library of 2,000 biologically active and FDA-approved compounds was 
performed using a control cell line expressing plain luciferase under the same promoter to 
evaluate the effect of compounds on luciferase activity. None were found to inhibit/enhance 
the luciferase activity under the experimental conditions, while 46 compounds were found 
to be toxic at 3 hr incubation and were excluded from consideration. Cell death was 
monitored simultaneously with luciferase assays by plating cells, in parallel, in the 
transparent bottom plates and performing two independent assays of cell viability along 
with luciferase: MTT reduction and phase contrast observation. In all cases, MTT agreed 
with our morphological assay. The use of robotics for cell plating results in uniform 
concentration of cells along the plate, and we have found after validation no need to 
continue normalization to the cell protein. As one might expect, additional manipulations in 
the same well result in increasing the errors in following activity measurements as we 
established during the HTS optimization. 
Further HTS screens are performed with two reporters in parallel, e.g. Neh2-luc and HIF1 
ODD-luc (see 2.2), in this case each reporter serves as a control for the other. Hits that are 
equally active in both reporters are excluded from further consideration (could be either 
metal chelators, redox active compounds, or proteasomal inhibitors). Hits that do not 
overlap are subject to further studies. In the particular case of HTS for non-alkylating Nrf2 
activators, hits are passed through the sructural filters to remove pro-oxidant, alkylating 
and other reactive motifs recently described by Baell & Holloway 2010. 
2.1.5 Challenge to find specific Nrf2 stabilizers: Advantages of real-time monitoring 
A major challenge in the development of effective Nrf2 activators is to identify those that 
lead specifically to Nrf2 stabilization and subsequent promoter activation, without imposing 
general oxidative/electrophilic stress. Such activators should exhibit higher affinity for 
Keap1 and work by competing with Nrf2 Neh-2 domain for Keap binding. The novel 
reporter for the first time provides the possibility of real time monitoring for changes in the 
stability of Nrf2 in the form of the luciferase labeled Neh2 domain. By following the kinetics 
of reporter activation one may expect to discriminate the mechanism of action of various 
Nrf2 activators, i.e. direct activators will exert immediate effects, while those acting 
indirectly will show lag-periods of different durations. Kinetics of reporter activation were 
measured by adding varied fixed concentrations of an inhibitor at different time points 
followed by simultaneous cell lysis and activity measurement in the whole 96-well plate; 
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this assay format minimizes experimental error originating from the well-known instability 
of a luciferase reagent. 
There are 6 types of experimentally observed kinetics of reporter activation (Fig.4).  
Type 1 is characteristic for alkylating agents such as sulforaphane, pyrithione, auranofin, etc. 
and shows an immediate linear increase in reporter signal in a concentration-dependent 
manner, and eventually reaches a threshold plateau (determined as a background signal 
magnitude in the control wild-type luciferase line).  
Type 2 shows lag-periods that shorten with rising concentrations and eventually disappear 
pointing to a switch in the rate-limiting step to the one affected by the added compound: 
this time-course is typical for proteasomal inhibitors and is observed for both Neh2-luc and 
HIF ODD-luc reporters (see Fig.1 in Smirnova et al, 2011).  
Type 3 shows a prolonged lag-period which duration shortens with rising concentrations to 
a some limit, but never disappears: such time-course indicates that the drug effects on a step 
with a limited contribution to the rate-limiting step. It has been seen only for cadmium 
among the activators studied: the duration of a lag-period was decrerased to 1 hr, and the 
subsequent increase in cadmium concentration had no effect.  
Type 4 shows prolonged lag-period, which duration is concentration independent. This type 
is characteristic for drugs working either upstream of Nrf2 stabilization step (such as Hsp90 
inhibitors showing 3 hr lag-period), or those drugs which must be initially oxidized to be 
able to modify Keap1 thiols (catechol with 20 min lag-period, or o-phenylene diamine with 
40 min lag-period).  
 
 
Fig. 4. Schematic representation of various types of reporter activation time-course (see text 
for explanation). Arrows indicate rising concentrations of Nrf2 activator, [A]; red thresholds 
show maximum reporter activation determined using a control cell line expressing wild-
type luciferase under the same promoter. 
Type 5 has been observed for two best hits in Spectrum library, nordihydroguaiaretic acid 
(NDGA) and fisetin, and shows an immediate switch-type response: there is negligible 
growth in signal up to a specific concentration (ca. 1.5-2 M) which brings the system to the 
maximum rate of signal increase. At this point, we can speculate that Keap1 serves as a 
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redox sensor, possibly via zinc atom bound to some of its thiols. There is evidence for zinc 
presence in vitro for recombinant Keap1, no data available on zinc binding to Keap1 in vivo. 
Future studies are necessary to clarify the target for these two compounds, which were 
confirmed to be extremely potent Nrf2 stabilizers (Smirnova et al 2011).  
 
 
 
Fig. 5. Gedunin (Left: A & B) and 7-deacetoxy-7oxokhivorin (Right) docking into Keap1 in 
comparison with the corresponding portion of Neh2 16-mer peptide (green). Docking 
experiments are performed using the CDOCKER algorithm, followed by force field 
minimization and binding energy calculations using the molecular mechanics algorithm 
CHARMm (as implemented in Discovery Studio 2.5, Accelrys, San Diego, CA). The crystal 
structure of the human Keap1 kelch domain with the bound 16-mer peptide of human Neh2 
(2FLU.pdb) with polar hydrogen atoms added was used as the starting template structure. 
Type 6 is the one that is most promising in terms of specific Nrf2 stabilization: a time-course 
with a concentration dependent re-equilibration plateau is usually a characteristic of 
competitive binding. This type of kinetics has been observed for gedunin and some of its 
derivatives. Gedunin fits perfectly into the same Keap1 binding pocket as Nrf2 closely 
following the bending of the 83FEGTE79 portion of Nrf2 peptide (Fig. 5 left). Moreover, its 
oxykhivorin analog with Michael‘s motif removed and replaced with two acetoxy-groups 
fits just perfectly, and is a more powerful activator of the Neh2-reporter than gedunin itself 
(Fig.5 right). 
We consider targeting the site of Neh2 binding in Keap1 as the most promising approach for 
the development of Nrf2 activators not imposing general oxidative stress. Another approach 
has been recently proposed by Wu et al (2010) who constructed a model of Keap1 including 
intervening region. Targeting this region one may expect to disturb Keap1 conformation in 
such a way that Nrf2 is released from the complex. This approach in general is less specific 
since Nrf2 is not the one client of Keap1.  
The authors performed virtual screening using their model and identified a number of 
structures showing decent docking scores (Fig. 6). Experimental testing of the identified 
compounds showed that only B10, B31, and B40 are good inducers of Nrf2-dependent 
genes. The confirmed hits are redox-active molecules and their effect on Keap1-Nrf2 
interaction may be not specific.  
Phe83-Glu82-Gly81-Thr80-Glu79Gedunin
A
B
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Fig. 6. Virtual hits targeting intervening region of Keap1 (Wu et al 2010). 
2.1.6 Criteria for selection of compounds for hit-to-lead program 
Depending on a particular goal, an algorithm for drug development efforts will involve a 
number of steps confirming the nature of the drug action mechanism. For example, if our 
goal is to develop Nrf2 specific activators that work specifically via disruption of Nrf2-
Keap1 interaction by competitively displacing the Neh2-portion of Nrf2, and not by non-
specific alkylation of Keap1 thiols, we must perform biological analysis to confirm this. The 
detailed structure-activity relationship studies (SAR) will employ (a) concentration titration 
experiments; (b) time-course of reporter activation; (c) in silico modeling; the hits obtained 
from screening the library will be used to help refine the in silico model; (d) Keap1 labeling 
experiments in the presence of selected hits to prove the non-alkylating nature of activation 
(see Smirnova et al 2011 Fig. S5A & B and protocol therein); (e) hits testing for the ability to 
upregulate Nrf2-dependent genes (RT-PCR); (f) evaluation of toxicity using primary culture 
neurons;  (g) hits that upregulate Nrf2 may be analyzed by microarray for non-specific 
activation of Nrf2-independent pathways; (h) hits that are neuroprotective in vitro are tested 
for ADME (Absorption, Distribution, Metabolism and Elimination).  
We have chosen two of our hits from Spectrum library – NDGA and gedunin for hit-to-lead 
program which is currently in progress. Both compounds are the key components of well 
known herbal medicines used for centuries by Native Amrecians (chapparal) and Indians 
(neem tree), respectively. For both compounds, ADME studies have been already done, and 
the compounds are neuroprotective in the in vivo model of MPTP-induced toxicity.     
In vitro ADME studies have always played a critical role in optimizing the pharmacokinetics 
(PK) properties of lead compounds thereby increasing their success rate (Thompson 2000). 
The ideal PK properties for an oral drug are favorable bioavailability, clearance and 
metabolic stability to provide adequate systemic exposure to elicit a pharmacodynamic 
response with low potential for dose-dependent toxicities. These in vivo properties should be 
assessed as early as practical using in vitro ADME prediction tools (Balani et al 2005). In 
1991, PK properties were attributed to more failure of drugs (40%) than efficacy or safety in 
clinical trials. With the application of advanced ADME techniques, the contribution of PK 
properties resulting in drug failure dropped dramatically to 10% in 2000 (Kola & Landis 
2004). Recently, in vitro ADME and cytotoxicity screening assays have been incorporated 
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with structure-activity relationship (SAR) studies in the earliest stages of drug discovery. 
The incorporation of early, high throughput ADME screening in parallel with efficacy 
screening has significantly reduced cycle time involved in moving compounds from “hit” to 
“lead” status. 
2.2 Cell-based screening using HIF1 ODD-luc reporter system  
Major advantage of cell-based screens is that we automatically exclude non-permeable and 
toxic compounds because they provide either no activation or even lower the background 
signal. In addition, there is no need to specifically formulate the composition of a reaction 
medium for an enzymatic reaction because the intracellular medium of cell lines is very 
close to that existing in the human body. Another advantage is that compared to in vitro 
enzymatic assay we rule out enzyme stability problem. The best example for this is the 
reaction catalyzed by HIF prolyl hydroxylase (HIF PHD). Below we present a detailed 
comparison of enzymatic screens versus cell-based screen for HIF1 activators working via 
inhibition of HIF PHD. 
2.2.1 HIF and HIF prolyl hydroxylase: HTS assay development problems 
Hypoxia-inducible factor (HIF) is a transcriptional factor that regulates gene expression in 
mammalian development, physiology and disease pathogenesis (Wang et al 1995). HIF 
consists of an oxygen-sensitive -subunit and a continuously expressed -subunit. HIF-1 is 
induced and stabilized in hypoxic conditions and functions as a master regulator of oxygen 
homeostasis. HIF-1 proteolysis is mediated via hydroxylation of two highly conserved Pro 
residues, which causes its direct interaction with von Hippel-Lindau protein (VHL). HIF-1 
hydroxylation is catalyzed by human prolyl-4-hydroxylases (PHDs).  Pro564 is located in the 
so called oxygen degradable domain (ODD) and is considered as the major site for 
hydroxylation catalyzed by all PHD isoforms. For HIF PDHs, the general reaction mechanism 
(Solomon et al 2000) includes activation of molecular oxygen to convert -ketoglutarate into 
succinate and CO2 while hydroxylating the prime substrate, HIF- subunit (Kaelin 2005). The 
reaction proceeds via the formation of oxoferryl-intermediate as shown in Fig.7.  
The proposed mechanism is based on the reported incorporation of 18O into HIF- substrate 
and succinate, the available crystal structures for PHD2, and the recent stopped-flow 
kinetics for taurine/-ketoglutarate dioxygenase and prolyl-4-hydroxylase from 
Parameticum bursaria Chlorella virus 1(Price et al 2005). The mechanism suggests the initial 
binding of iron to the active site, then -ketoglutarate coordination via C-1 carboxylate and 
ketone oxygen by iron, followed by the binding of HIF peptide (as a substrate) which results 
in displacing the water molecule from the 6th coordination position. This displacement 
guarantees oxygen binding and activation.  The uncoordinated oxygen of the bound oxygen 
attacks the ketone carbonyl of -ketoglutarate to form a bicyclic Fe(IV)-peroxyhemiketal 
complex, in which decarboxylation occurs concomitantly with formation of an oxo-ferryl 
(Fe(IV)=O) intermediate. The latter one hydroxylates proline via a substrate radical 
intermediate as evidenced by the formation of prolyl radical: i.e. oxo-ferryl attacks proline 
residue to withdraw hydrogen atom, and then introduces the hydroxyl radical. The 
presence of the water molecule in the 6th position does not prevent oxygen from binding and 
activation completely: in the absence of the substrate the enzymes of this class are known to 
catalyze the so called uncoupled reaction, i.e. ketoglutarate decarboxylation in the absence 
of HIF or HIF peptide. However, the rate of the reaction is rather slow.  
www.intechopen.com
 Novel Approach to High Throughput Screening for Activators of Transcription Factors 305 
 
Fig. 7. Schematic presentation of two half-reactions of HIF prolyl hydroxylase catalytic cycle 
(see detailed explanation below). The reaction substrates are ketoglutarate, oxygen and HIF 
or HIF peptide, and the reaction products are succinate, cabon dioxide, and hydroxylated 
HIF or HIF peptide.  
PHDs 1-3 (also known as EGLN 2,1, and 3) in human are represented by three isozymes 
with catalytic domains very homologous to each other (Bruick & McKnight 2001). PHD3 
contains the catalytic domain only, contrary to PHD1 and PHD2, which have additional N-
terminal domains. The crystal structure of PHD2 catalytic domain was resolved by two 
independent groups.  PHD2 exists as a monomer in solution. The enzyme contains double-
stranded -helix core fold common to the Fe(II)-KG-dependent dioxygenase family. The 
active site comprises a relatively deep pocket compared to other KG oxygenases. Iron is 
coordinated in an octahedral manner by His-313, His-374 and Asp-313, inhibitor (occupying 
two sites) and water molecule (Fig.8). The similarity in the structure of catalytic domains of 
PHDs1-3 and identical KG binding residues (according to the homology modeling) makes 
the task of developing specific inhibitors based on KG analogues doubtful.  
 
   
Fig. 8. Displacement of active site water (left) upon binding of HIF peptide (right) initiates 
oxygen binding and the catalytic cycle of ketoglutarate decarboxylation accompanied by 
formation of ferryl iron, subtraction of hydrogen from Proline 564, and subsequent 
hydroxylation of the latter.  
There are 3 different ways to assay PHD activity (Hewitson et al 2007): 
 The assay of the first half-reaction substrates and products (O2 and a-ketoglutarate 
consumption; CO2 evolution, succinate production); this format should account for the 
uncoupled reaction, which is non-specific. 
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 The assay of the second half-reaction oxidized product (mass-spec of hydroxylated 
peptides); mass-spec analysis is difficult to make suitable for HTS format. 
 The so-called “capture assay” monitoring interaction of the hydroxylated product with 
VHL; requires recombinant HIF, reticulocyte-produced VHL, protein/peptide labelling 
and corresponding antibodies.  
The most reliable way to monitor the formation of hydroxylated product is either by mass-
spectrometry, or using the “capture assay“. The latter is known in three different formats: 
 End-point immunochemical assay is based upon the tight interaction between pVHL 
and the hydroxylated Pro564 of HIF-1. Iimmobilized HIF-peptide which, after 
hydroxylation, is recognized by the thioredoxin-labeled VHL-elongin B-elongin C 
complex (expressed in E.coli and purified), which is its turn, is detected by anti-
thioredoxin antibodies by the method of double antibodies with the second, peroxidase-
labeled, antibodies.  
  Continuous fluorescence polarization assay: HIF-peptide modified with a fluorescent 
label upon capture by VHL-elongin B-elongin C shows higher polarization signal (Cho 
et al 2005).  
  Continuous homogeneous time-resolved fluorescence resonance energy transfer (TR-
FRET) assay: VCB-Eu complex recognizes hydroxylated P564-HIF-1 peptide, 
preliminary biotinylated, followed by interaction with streptavidin labeled 
allophycocyanin (Fig.9). This assay, developed by Amgen team, is the best one in terms 
of sensitivity and applicability for HTS. The assay, in addition to other expensive 
reagents, utilizes Europium (Dao et al 2009).  
All enzymatic assays are based on the use of PHD2 recombinant enzyme produced in either 
baculovirus or E.coli expression system. High throughput screening for PHD inhibitors 
using an enzyme assay is a challenge both in terms of the enzyme source and the assay 
format. The enzymatic activity and stability of purified PHD is very low (Tuckerman et al 
2004), and enzyme assays suitable for HTS require large quantities of recombinant enzyme 
supplemented with iron. One of challenges in the search for selective HIF PHD inhibitors or 
other regulators of HIF stability is to discriminate between non-specific iron chelation in 
solution and specific iron chelation inside the active center of the PHD enzyme (see 2.2.4). 
Given the non-physiological conditions under which screening for inhibitors occurs with 
recombinant PHD2, it is not surprising that the IC50 value determined in the enzyme in vitro 
assay did not correlate with  the IC50 for VEGF activation reported in the same study 
(Warshakoon et al. 2006d). Another limitation is the use of a 19-mer HIF peptide, whose 
affinity for the HIF PHDs is orders of magnitude lesser than the full length protein. So far 
only Amgen team used recombinant HIF protein in HTS of their internal collection, 
although again they had been varying the concentration of KG, not HIF, when determining 
the inhibition constant for their best hit (Tegley et al. 2008). A negative consequence of the 
test tube strategy is the assay format is more likely to yield inhibitors competitive with 
respect to KG than those competing with HIF itself.  
The screening for PHD2 inhibitors based on enzymatic assays with recombinant PHD2 was 
performed by Fibrogen, Procter&Gamble, Amgen, and some other groups.  The 
Procter&Gamble team published 4 papers analyzing structure-activity relationship (SAR) 
for 3 different groups of compounds possessing clear iron binding motifs that dock into the 
PHD2 active site. The hydroxylation assay was performed by mass-spectrometry. In 
addition, the ability of some inhibitors to induce VEGF was judged by a VEGF ELISA using 
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HEK293 cells. The total number of compounds reported was ca.50. The screening for PHD 
inhibitors based on the KG mimetic structures yielded a number of different classes of 
inhibitors with the inhibition constants in the µM range. The best inhibition constant among 
substituted pyridine derivatives was exhibited by p-chloro phenyl-substituted 5-pyridine 
carboxyamide (15 µM) and those with the pyrazole moiety in the 5th position of the pyridine 
ring (5-20 µM) (Warshakoon et al, 2006a); the further work resulted in the significantly 
improved affinity (1-2 µM) of the newly designed inhibitors of pyrazolopyrimidines series 
(Warshakoon et al, 2006a). Imidazo[1,2-a]pyridine derivatives showed the apparent 
inhibition constants in the 4-27 M range (Warshakoon et al, 2006b), and 8-
hydroxyquinoline derivates exhibited the apparent inhibition constants in the range of 3-10 
µM (Warshakoon et al, 2006c). However, taking into account that the screening for potential 
inhibitors was performed using a 19-mer peptide, which shows at least 1 order of 
magnitude worse Km than HIF-ODD, the range of the apparent inhibitor constants obtained 
may be insufficient for the inhibition of the enzyme activity in vivo. 
Very recently, the Amgen team developed a time-resolved fluorescence resonance energy 
transfer-based assay based on interaction of the hydroxylated HIF peptide with VHL and 
performed HTS of their “internal compounds collection” to reveal a lead compound of IC50 
of ca. 72 nM from a novel hydroxyl-thiazole class, followed by lead optimization. 30 new 
derivatives have been synthesized and assayed. The inhibition constant was determined 
from single-point measurements done in triplicate at pH 6.0, which was found to be optimal 
for the in vitro reaction catalyzed by human full-size recombinant PHD2. The best inhibitors 
have a long hydrophobic tail that screens the entrance to the active site. Flexibility of the tail 
(benzyl instead of phenyl) enhances affinity by orders of magnitude as the IC50 is improved 
from dozens nM to single digits. These are the best inhibitors reported in literature thus far. 
The conformation of recombinant PHD2 may be different from that of the native enzyme, in 
addition, PHD2 like all enzymes of this family is highly unstable in the absence of reducing 
agents such as DTT. The recently reported crystal structure of PHD2 with a 17-mer HIF 
peptide (Chowdhury et al. 2009) shows no active site water displacement, which appears to 
be a mandatory requirement for the initiation of the catalytic cycle. Given these biases, it is 
not surprising that all PHD inhibitors developed using the recombinant enzyme explored 
only the KG-binding motif inside PHD2 active site and had a carboxyl group interacting 
with Arg-383 in addition to a clearly defined iron-binding motif (Tegley et al. 2008, 
Warshakoon et al. 2006a, Warshakoon et al. 2006b, Warshakoon et al. 2006c, Warshakoon et 
al. 2006d, Ivan et al. 2002). The reaction mixture has to be supplemented with excess of iron, 
alpha-ketoglutarate, and HIF peptide, making the selection of mild inhibitors impossible. 
Majority of PHD inhibitors identified in HTS are presented by iron chelators. The only 
exception so far is Compound A with IC50,=0.032 M (see Fig.9 right) identified by Amgen 
team using the newly developed assay (Fig.9), however, the core motif will not pass the 
filters recently described by Baell and Holloway, 2010.   
One of disadvantages of enzymatic assay is that despite the apparent specificity, the hits 
identified in HTS may potentially target other enzymes of the same class. In particular, 
human genome has more than 70 genes of putative non-heme iron dioxygenases, and there 
is no principal difference in organization of the active sites of these enzymes. As a rule, the 
major difference is in the access to the active sites. There are three different forms of HIF (1-
3) and three PHD isoforms, and all data reported so far on enzyme specificty using HIF 
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peptides and recombinant enzymes give no clue on the preference for a particular substrate 
for a PHD isoform. On the other hand, the study of HIF-PHD interaction in yeast two hybrid 
system indicated principal differences existing among PHD isoforms with respect to 
recognition of HIF isoforms (Landazuri et al 2006). The latter observations are in agreement 
with our results obtained with HIF2 ODD-luc and HIF3 ODD-luc reporters showing that 
HIF3 is not recognized by PHD1 and PHD2. Therefore, running enzymatic assays with 
PHD2 and HIF peptides does not give a true picture of enzyme specificity and cannot be 
used for development of isozyme-specific inhibitors.  
 
 
Fig. 9. Schematic presentation of TR-FRET assay (left) developed by Amgen team to monitor 
the activity of HIF prolyl hydroxylase. The assay employes biotin-labeled HIF, Eu-labeled 
VHL protein, as well al APC-labeled streptavidin, in addition to the recombinant PHD2 
used as a catalyst of the first enzymatic step. The assay was successfully used for HTS 
purposes: an inhibitor (E)-2-(4-hydroxy-5-(2-(phenylsulfonyl)acetylimino)-4,5-
dihydrothiophen-3-yl)acetic acid specific for KG binding site has been developed (right, 
Compound A), and later dipeptidyl-quinolones (see compound 12{1,1,2}) specific to PHD1 
and 3, and 10-fold less specific to PHD2 (Murray et al 2010). 
2.2.2 HIF1 ODD-luciferase reporter construction (Safran et al 2006, Smirnova et al 
2010) 
Two primary modes of screening for HIF activators have been well described: a 
recombinant enzyme-based screen for PHD2 inhibitors (used by Fibrogen (Ivan et al. 2002), 
Amgen (Tegley et al. 2008, Allen et al 2008)), Procter and Gamble Pharmaceuticals Inc. 
(Warshakoon et al. 2006a, Warshakoon et al. 2006b, Warshakoon et al. 2006c, Warshakoon et 
al. 2006d), and other teams (Nangaku et al. 2007)); and a cell-based screen using HRE-
luciferase reporter construct used by a number of labs including our own. 
The cell-based assay with HRE-luc reporter system, a promoter-reporter construct that 
contained 68 bp of a known hypoxia and HIF-1 regulated gene, enolase, containing a wild 
type HRE (5’-RCTGT-3’), is a widely used approach for screening of HIF activators with 
diverse mechanisms of action (Semenza et al. 1996). A reporter system is based on 
transfected immortalized hippocampal neuroblast cell line (HT22) and allows screening for 
a broad spectrum of compounds that include: activators of HIF transcription; activators of 
HIF binding to HRE; and effectors of HIF protein stability (PHD inhibitors, pVHL & 
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proteasome inhibitors). The manual screen of Spectrum library performed in this laboratory 
using HRE-luc/HT22 line took half a year and resulted in 43 hits. However, in our hands, 
the cell line’s response to positive controls decreases after 7 passages, making the system not 
suitable for a robotic HTS on 384-well plates.  
Taking into account the low specific activity of recombinant enzymes, and the inadequacy of 
interpretation of the inhibition constant generated using different types of enzyme in vitro 
assays, we developed a cell-based reporter system for HTS of ODD-luc stability, a variant of 
the cell-based “capture” assay, and accomplished a screen of 85,000 structurally diverse 
compounds (Smirnova et al 2010). Cell-based assay for HIF1 activators working via 
inhibition of HIF PHDs employs the same strategy as the one used for screening of Nrf2 
activators.  The HIF1 ODD-luc reporter system is equivalent to in vivo capture assay 
monitored by consumption of a labeled substrate (ODD-luciferase) (see Fig. 10 left). The 
reporter system II (Fig. 10 right) consists of the HIF-1 gene fragment encoding the oxygen 
degradable domain (ODD) containing the key proline residue followed by luciferase gene 
(luc) (Safran et al 2006). The regulation of luciferase protein stability in this reporter system 
is the same as the physiological activation of HIF: hydroxylation of oxygen-degradable 
domain (ODD, which contains 530-653 a.a. of HIF1 results in recognition of the ODD-luc 
fusion protein by VHL followed by its ubiqutinylation and proteasomal degradation 
(Fig.10), and as we present below, the approach proved to be productive for HTS purposes.   
 
 
Fig. 10. The principle of HIF1 ODD-luc reporter performance (left) and construction of the 
two controls (right). 
The reporter cell lines constitutively expressing HIF1 ODD-luc (human neuroblastoma, SH-
SY5Y) were stable for more than 1 year without significant change in their response to 
canonical PHD inhibitors such as DFO, dihydroxybenzoate, dimethyloxalylglycine, and 
ciclopirox (see Smirnova et al 2010, Fig.1B).  In order to verify the specificity of luciferase 
changes as an assay for PHD activity, several control lines were developed: the control line I 
expressing wild-type luciferase under the control of PCMV-promoter,  and the control line II 
expressing ODD-luc with proline 564 and 567 Mutated to Ala, which generates luciferase 
fusion that cannot be degraded. Both controls experimentally identify a threshold level of 
ODD-luc protein attainable in these cells. The background signal for the wild-type HIF 
ODD-luc line (PYIP) corresponds to approximately 5-6% of the ODD-luc levels in the control 
lines with wild-type luciferase and AYIA line (double mutant P564A/P567A line) (Fig.10 
right).  Treatment with 10 M ciclopirox results in a 10-fold increase of a background signal 
for the ODD-luc reporter (PYIP line), i.e. reaches almost 50% of the threshold value (see 
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Smirnova et al 2010, Fig.2). These particular conditions are ideal for HTS as they promote 
the selection of both weaker and more potent inhibitors than ciclopirox.   
2.2.3 Determination of inhibition constants from kinetics of HIF1 ODD-luciferase 
reporter activation   
In accord with validation studies, the HIF ODD-luciferase reporter system is controlled by 
the rate of PHD-catalyzed reaction:  the response of the ODD-luc reporter to canonical HIF 
PHD inhibitors, and the increased stability of single-point mutant reporters in accord with 
the predictions (see Smirnova et al 2010), provided confidence that this system could be 
utilized for screening for novel small molecule HIF PHD inhibitors. From an enzyme 
kinetics point of view, the HIF ODD-luciferase reporter system is a “capture assay” 
monitored by the consumption of a substrate, the heterologously expressed HIF ODD-
luciferase fusion protein. As we show below, the reporter activation kinetics can be used to 
determine an apparent inhibition constant for a particular compound. In the kinetic regime, 
i.e. monitoring the time-course of luminescence changes (Fig.11), the ODD-luc reporter 
system permits quantitative characterization of promoter capacity (Ko, rate of fusion protein 
generation), enzyme activity, and inhibition constant determination. The rate of fusion 
accumulation equals to the rate of its production (Ko) minus the rate of rate-limiting step, 
controlled by HIF PHDs, which obeys Michaelis-Menten kinetics, as follows:  
 0 1[ ]/ - [ ][ ]/{ (1 [ ]/ ) [ ]}m iv d ODDluc dt K k PHD ODDluc K I K ODDluc      (1) 
where Km is the inhibition constant for a competitive inhibitor, k1  is rate coefficient, 
[PHD] and [ODD-luc] are the concentrations of the enzyme and substrate, respectively.  
The background luminescence signal calibrated with recombinant luciferase allows us to 
estimate the steady-state concentration of the ODD-luc fusion protein. Under the conditions 
used the steady-state value of 60 rlu (relative light units) corresponds to 1 pg luciferase 
protein; dividing this number by the total cell volume taken as a single cell volume (233 3) 
multiplied by 30,000 cells/well density (numer of cells in a 96 well dish), we get the ODD-
luc fusion protein steady-state concentration equal to 2.3 nM, which is way below all 
reported Km values for HIF1 (Ivan et al 2002, Tuckerman et al 2004, Koivunen et al 2006). 
Therefore, we work under non-saturating conditions with respect to HIF substrate, i.e. 
optimal conditions for selecting inhibitors competitive against HIF substrate. Moreover, as 
compared to the in vitro assay, which uses a 19 amino acid peptide fragment surrounding 
the oxygen dependent domain (ODD), our ODD-luciferase construct contains 123 amino 
acid acids, and thus more closely emulates the behavior of native HIF. We can consider the 
initial concentration of fusion much lower than Km and ignore it in the rate equation:  
 0 1[ ]/ [ ][ ]/ (1 [ ]/ )m iv d ODDluc dt K k PHD ODDluc K I K     (2) 
The capacity of promoter, K0 can be determined under the conditions of total inhibition of 
PHD activity by means of complete iron deprivation achieved in the presence of high 
concentrations of ciclopirox, i.e. when the increase in the ciclopirox concentrations give no 
further increase in the rate of luciferase signal growth (Fig.11). The intracellular enzyme 
activity (k1[PHD]/Km) can be also determined by dividing the rate of fusion protein 
accumulation by the steady-state concentration of the fusion protein determined directly 
from one and the same experiment in luciferase units, without recalculation for the cellular 
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volume,  and corresponds to 0.05 min-1. The linear plot of 1/(K0 – v) versus the inhibitor 
concentration gives the value of the apparent inhibition constant as the intercept on X-axis 
(Fig.12): 
 0 1 01 /( ) (1 [ ]/ ) / [ ][ ]m iK v K I K k PHD ODDluc    (Eq.3) 
The apparent inhibition constants determined as an intercept on X-axis for compound 7 and 
DMOG are 0.0012 mM and 1.3 mM, respectively (see Fig.12), which is in agreement with 
previous observations on DMOG biological effects exerted in the millimolar range and IC50 
reported for PHD2 in vitro assay. 
The developed approach is good only if the activation effect is significant, at least 3-fold and 
higher over the background luminescence, otherwise the experimental error of kinetic 
measurements is too high to perform the above described calculations. 
 
 
Fig. 11. Experimental kinetics of reporter activation for ciclopirox (complete iron 
deprivation, which permits determination of the promoter capacity, K0), 
dimethyloxalylglycine (DMOG), ketoglutarate analog competing with the latter for the 
binding in the active center of PHD, and one of the best hits in HTS (Smirnova et al, 2010), 
compound 7 (formula in Fig.12). 
2.2.4 Rationale for discriminating between specific and non-specific PHD inhibition  
Since the enzyme controlling the rate-limiting step of reporter activation is iron dependent, 
any iron chelator will come up as a hit in HTS. To discriminate between the non-specific 
iron chelation in solution and iron coordination by a chelator in the active site of PHD2 we 
had to develop a rationale. One of the possibilities to evaluate specificity of the reporter 
response could be the comparison of concentration titration curves in the presence and 
absence of extra iron. Only specific PHD inhibitors will act at concentrations lower than that 
of the added iron. Although this approach may potentially yield specific PHD inhibitors 
right away, it creates a serious experimental problem: cell lines are extremely sensitive to the 
presence of more than 2 M extra iron in the medium, which possibly catalyzes Fenton 
reaction resulting in cell death within hours of incubation. Another approach is to compare 
reporter activation parameters with the iron chelation ability in solution for a set of 
compounds of similar structure. If the iron chelation ability of the inhibitors is linearly 
proportional to HIF activation parameters, it can be safely concluded that the inhibitors 
simply inactivate PHDs through their ability to chelate iron non-specifically. If on the other 
hand activation of HIF and iron chelation ability are not proportional then the inhibitors act 
on PHD through a more specific mechanism. 
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Fig. 12. Calculation of apparent inhibition constants for compound 7 and DMOG using a 
modified Dixon plot. 
To account for iron chelation in solution one should determine the iron binding constant in a 
model system, for example by displacement of calcein from its complex with iron upon 
addition of a particular compound monitored by fluorescence (excitation 490 nm, emission 
523 nm, cut-off 515 nm) on a Spectramax M5e platereader (Molecular Devices). To linearize 
the fitting equation we introduce parameter Y as the ratio of calcein-iron complex to free 
calcein, which can be determined directly from our experiments: Y = [Fe-Calcein]/[Calcein]. 
The apparent binding constant for calcein (ca.50 nM) was determined from Fe titration 
curve for 1 M calcein in 5 mM Tris-HCl buffer, pH 7.5 (Fig.13 left). The ratio between the 
iron binding constant for calcein and a particular compound KQ/KCa can be estimated by 
fitting the titration curve into the dependence of [Fe]o vs. Y, where Y=[Ca-Fe]/[Ca] is a ratio of 
calcein-bound Fe to free (fluorescent) calcein: 
 [ ] [ ] /( 1) [ ] /( / )Ca Q CaFe o K Y Ca oY Y Q oY Y K K      (4) 
The protocol included addition of 50 µL of Iron in various concentrations  0.5 µM – 2.0 µM to 
the buffer solution, then the addition of 50 µL calcein so that final concentration of calcein is 
1 µM; the addition of 50 µL compound of interest in various concentrations, and then taking 
end point readings at 20 min incubation. Range of compound concentration was determined 
through how well the compound liberated calcein from its complex with iron (Fig.13 right). 
Besides the equilibrium constant, the association rate constant (kinetic coefficient) can be 
determined as the second order rate constant for calcein displacement kinetics from its 
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complex with iron (1 M:1 M) upon addition of an oxyquinoline (5-20 M), i.e. calculated 
from the slope of a linear plot of the initial rate of calcein release vs. the concentration of 
oxyquinoline added. This parameter can be used as a kinetic characteristic of iron binding.  
Once the iron binding constants are determined, one can plot the reporter activation 
parameters versus inverse inhibition constant, or iron association constant. In both cases, 
IC50 determined from the concentration titration curve is the correct parameter to plot (Fig. 
14). The activation magnitude is not a perfect parameter for structure-activity relationship 
(SAR) studies, because as we wrote earlier, there is a threshold for reporter activation, and if 
incubation is not short, the reporter hits the plateau, which is one and the same for all hits.  
 
 
Fig. 13. Determination of  iron binding constant for calcein (left) and 7,8 dihydroflavone 
(right) as an example of iron-binding compound.  
As seen in Fig. 14, there is a parallel in iron chelation properties and IC50 for majority of 
branched oxyquinolines studied, except for 4 compounds which deviate from the linear 
dependence (##1,4,7,8). All these have a specific branch similar to that shown in Fig. 12 for 
compounf 7. Compounds 7 and 8 were taken for biological analysis along with compound 
10, which was used as a negative control, because despite its iron binding capacity and cell 
permeability is as good as for compounds 7 and 8, this compound is not a specific PHD 
inhibitor.  
A similar approach can be used to rule out the effect of reducing or oxidative properties (say 
flavonoids). For this purpose, the rate constant for oxidation/reduction of ferro/ferricyanide, 
can be measured (not shown). The rate of reduction of dithionitrobenzoic acid can be used to 
account for disulfide reduction capacity of compounds uder study. 
2.2.5 Substrates and substrate specificity of HIF prolyl hydroxylases  
The data from the literature and that obtained in this laboratory unequivocally demonstrate 
that PHDs are important targets for medical intervention. This justifies the necessity of the 
development of HTS for PHD inhibitors, activators, specific and alternative substrates. The 
challenge is to develop inhibitors specific for each isoform, since very recently it became 
clear that the PHD isozymes have their specific substrates.  
HIF1 and HIF2 are established substrates for PHD2. PHD1 apparently is specific for Rpb1, 
the large subunit of RNA polymerase II, which carries the fundamental enzymatic activity 
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of the complex synthesizing all cellular mRNAs. Rpb1 is ubiquitylated and degraded in 
response to DNA lesions induced by UV light and high millimolar H2O2. Phosphorylation of 
Ser5 in Rpb1 is a prerequisite for Rpb1 ubiquitylation. It has been discovered that Pro1465 
hydroxylation catalyzed by PHD1 is necessary for subsequent  Ser5 phosphorylation of 
Rpb1 in response to oxidative stress. PHD2, in contrast, has an inhibitory effect on this 
modification (Mikhailova et al 2008). Recently, the Kaelin’s group (Zhang et al 2009) 
demonstrated a link between PHD1 and cyclin D1: PHD1 is estrogen-inducible in breast 
carcinoma cells and PHD1 inactivation decreases Cyclin D1 levels and suppresses 
mammary gland proliferation in vivo. Regulation of Cyclin D1 is a specific attribute of PHD1 
among the PHD proteins and is HIF-independent. Loss of PHD1 (but not PHD2) catalytic 
activity inhibits estrogen-dependent breast cancer tumorigenesis and can be rescued by 
exogenous Cyclin D1. PHD1 depletion also impairs the fitness of lung, brain, and 
hematopoietic cancer lines. These findings support the exploration of PHD1 inhibitors as 
therapeutics for estrogen-dependent breast cancer and other malignancies. PHD1 appears to 
be an attractive drug target because PHD1 is not essential in mammals. 
 
 
Fig. 14. Evaluation of iron chelation effect on inhibition parameters determined for branched 
oxyquinolines. Among all compounds of this group tested, only four (compounds 1,4,7,8) 
showed significant deviation from a linear dependence, and thus are considered as specific 
PHD inhibitors.  
PHD3 hydroxylates -adrenergic receptor (AR) (Xie et al 2009), the prototypic GPCR that 
play an important role in the regulation of cardiovascular and pulmonary function, and 
sustained AR down-regulation (and dysfunction) is associated with diseases such as heart 
failure and asthma. AR, in particular, enhances bronchodilation and alveolar fluid 
clearance (which increase O2 uptake), enhances cardiac output and peripheral vasodilation 
(which increase O2 delivery), and enhances cardioprotection and angiogenesis under 
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ischemic conditions, thereby effectively recapitulating the integrated physiological response 
to hypoxia. Up-regulation of the AR in response to hypoxia puts the function of the 
receptor in new light. The ability of the PHD3-pVHL hydroxylation and ubiquitylation 
pathway to regulate the 2AR and the implications of that regulation for the response to 
ischemia and hypoxia suggest previously unidentified targets in the treatment of 
cardiovascular and respiratory diseases. PHD3 is most abundant in cardiac and smooth 
muscle, where the AR is highly abundant in vivo. PHD3 expression is increased with 
aging.  
On one hand, the disadvantage of the cell-based assay is that there are 3 different isoforms 
of the enzyme, and reporter activation shows an integral inhibition of all three or the two 
most abundant (PHD1 and PHD2). On the other hand, the enzymatic assay is sensitive to 
the isoform-specificity only when the full-size protein substrate (HIF1) is used. The 
combination of cell-based HIF1 ODD-luc reporter assay with siRNA technique can give an 
answer on isoform specificity with respect to HIF1 and can be used to clarify the specificity 
of a particular drug candidate with respect to PHD isoform.  
Cell-based HTS is close to the actual reaction conditions in the cell, where concentration of 
HIF is at below nanomolar level and thus, permits selection of mild inhibitors. 
Computerized analysis of hits in the case of PHD inhibitors groups hits in accord with their 
core structure, which obviously is just a mimic of KG. The average number of hits from 
10,000 compound library is on the order of 30-40 compounds, and this low number (in 
comparison with Neh2-luc screen) permits manual classification. The comparison of the 
structures of various hit groups from HTS screen of 85,000 compounds demonstrated (1) the 
presence of a branched motif immediately attached to the iron chelation/coordination core, 
and (2) the effect of the linker length.  As shown in Fig.15, long or rigid branch, immediately 
attached to the iron-coordinating core, has a profound effect on HIF1 ODD-luc reporter 
activation. In the case of branched oxyquinolines, we were able to study structure-activity 
relationship in detail (Smirnova et al 2010), and to demonstrate the specific character of PHD 
inhibition by branched oxyquinolines (see compound 7 in Fig.12 & compounds 1,4,7,8 in 
Fig. 14). 
Structural analysis of the hits comprised of branched quinolines revealed that the general 
scaffold consists of three regions: the iron binding motif, linker, and the terminal groups that 
may serve for surface recognition among the various PHD isozymes (Figure 16).  Chemical 
modification on each of these regions will create a substantial molecular space for exploring 
the pharmacophoric requirements for PHD inhibitory activity and isoform selectivity with 
the aim to identify the advanced analogues with requisite physiochemical properties. 
Our current research is focused on optimization of the branched portion of 8-
hydroxyquinolines to develop isoform-specific PHD inhibitors, as shown in Fig.16. Iron-
binding groups can be represented by various iron-coordinating cores, and oxyquinolines 
are just an example chosen based on the ease of synthetic manipulations. As the iron-
binding groups can also contribute to the isozyme selectivity, one may investigate structural 
alterations in the portion that bears an Fe(II)-binding group by analogy with the known 
structures of PHD inhibitors mimicking ketoglutarate binding (see Fig.17D). It is known that 
less flexible structures can mimic bound conformation at the target binding site; moreover, 
structural rigidification reduces CYP450 interactions and hERG blocking activity, therefore 
allowing for improvement of ADMET characteristics of the proposed inhibitors. As could be 
envisioned, the core structure of 8-hydroxyquinoline might be constrained by incorporating 
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the 3,4-dihydrobenzoxazine ring, formed by connecting the 8-hydroxygroup and the 
nitrogen in the side chain. Notably, a few compounds of that type were defined by initial 
HTS as the substituted 3,4-dihydro-2H-pirydo[3,2-h]-1,3-benzoxazine shown in Fig. 17. 
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Fig. 15. Identification of branched hits mimicking PHD interaction with HIF peptide. 
Schematic representation of interaction mode of PYIP portion of HIF peptide with PHD2 
active site iron (A) and HTS hits of oxyquinoline group (B) and catechol group (C and D). 
Docking of HIF peptide into PHD2: (E) Overall view of hydroxylated HIF peptide docked 
into the PHD2 structure; (F) HIF peptide position with respect to the bound isoquinoline 
inhibitor. Docking studies have been performed using the available crystal structure of 
PHD2 (2G19) and hydroxylated HIF peptide as is, in its conformation in the complex with 
VHL (1LM8.pdb). The only restrain was the orientation and distance of Pro 564 hydroxyl 
oxygen from iron. The LAPYIP sequence fits into the active site entrance, while the rest of 
the C-terminal tail goes under the so called 23 loop. No minimization was performed on 
protein. The move of the loop down to cover HIF peptide is the predicted protein 
minimization result. Tyr565 and Ile566 are located just under the isoquinoline ring plane.  
Carboxy-group of FG-0041 interacts with active site Arg-383 in addition to chelation of iron. 
Benzoxazine hits chelate iron in the active site of PHD the same way. Reporter activation is 
sensitive to the lenght of a linker: the latter should be rather flexible and not long. Docking 
studies show that the branched portion mimics the position of PYIP sequence of HIF 
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peptide, and thus playing with this portion one can develop inhibitors specifically 
interacting with the entrance to the PHD active site. Such inhibitors will be able to 
discriminate between different PHD isoforms.  
 
 
Fig. 16. Variations in chemical structure of PHD inhibitors to improve interaction with the 
entrance to the enzyme active site. 
 
 
Fig. 17. Exploring 3-Substituted 3,4-dihydro-2H-pyrido[3,2-h]-1,3-benzoxazine hits from 
HTS (A-C). D: Fibrogen developed PHD inhibitor (FG-0041). E-F: Variantions in the 
branched portion of benzoxazines. 
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3. Conclusion 
The novel approach to HTS of transcription factor activators is extremely promising for the 
development of specific stabilizers of the corresponding transcription factor, because it is 
sensitive to the initial step in transcription factor stabilization. The magnitude and 
sensitivity of reporter assay permits selection of mild activators which provide “fine 
tuning”. The key characteristic of new reporter systems is the possibility to monitor reporter 
activation in real-time to support structure-activity relationship studies (see Figs. 4 & 11). 
No other reporter provides such a possibility, and no other reporter provides such 
sensitivity. For both reporters discussed, this new feature opens a way towards design of 
specific stabilizers of the corresponding transciption factor.  
We were first to predict the possibility of development of isoform-specific PHD inhibitors 
employing variations in the motif adjacent to the iron binding core based on the results of 
HTS (Smirnova et al 2010). This prediction was supported by the identified branched 
oxyquinolines, which were characterized as PHD specific inhibitors and were confirmed to 
exert the predicted biological effects. Our conclusion on the role of branched portion in 
recognition of different PHD isoforms has been experimentally confirmed in the recent 
publication from Amgen group: the branching peptide-like portions attached to the 
quinolone core (see Compound 12{1,1,2} in Fig.9) resulted in up to 10-fold difference in 
magnitude of inhibition of PHD2 and PHD1/PHD3 (Murray et al 2010). Hence, isoform-
specific PHD inhibitors can be constructed by optimizing the branching portion 
immediately adjacent to the iron-chelation core.  Ongoing work includes synthesis of 
branched derivatives (Fig. 17) to explore the possibility of developing isoform-specific 
inhibitors.  
We were first to demonstrate the direct effect of gedunins on Nrf2 activation as well as their 
perfect docking into Keap1 in place of Neh2 peptide. The latter discovery is promising in 
terms of future identification of non-electrophilic activators working by displacing of Nrf2 
from its complex with Keap1, without non-specific oxidation or covalent modification of 
Keap thiols among other cellular proteins.  
The collection of reporters available in the laboratory (HIF1 ODD-luc and its mutants, HIF2 
ODD-luc, HIF3 ODD-luc, Neh2-luc) permits their parallel use for HTS purposes, where each 
reporter plays the role of a control for each other. The new reporter assays combined with 
secondary biochemical analysis permit selection of drugs working at the first, selective step 
of transcription factor stabilization.  
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